Biovitrum Announces Future Roadmap - Increased Focus on Specialist Care Diseases

Stockholm, November 7, 2007. At its Capital Markets Day in Stockholm,
the Swedish biopharma company Biovitrum (OMX: BVT) announced its
roadmap for creating long term value. The three corner stones of the
new strategy are:

  * Re-focus R&D portfolio towards projects in diseases treated by
    specialists, capitalizing more on its biopharmaceutical
    competence.
  * Develop in-house specialist care projects all the way to the
    market and out-license primary care R&D projects.
  * Increase revenues and expand the portfolio of marketed products
    through geographical expansion and by acquiring new products.

The reasoning behind the new strategy was described by Biovitrum's
CEO Martin Nicklasson. In summary, Nicklasson highlighted that there
are many specialist care areas with high unmet medical needs with a
favourable access to market and requiring less extensive development
programmes. In addition, marketing and sales effort will be more
focused and less costly. It also enlarges the medical scope since
both biopharmaceuticals and small molecules can be pursued.

Biovitrum also announced the exercise of its option to partner, with
Syntonix/Biogen Idec, on Factor VIIIFc with prolonged half-life for
the treatment of hemophilia A, aiming at significantly improving
patient convenience."The Factor VIIIFc project fits strategically very well with our
already strong commitment in the hemophilia business", commented CEO
Martin Nicklasson. "Biovitrum has been very successful within this
specialist care area and we will continue to develop and strengthen
this position. It's an appealing area, with stable growth and the
continued need for medically improved products".

The Company's hemophilia business also includes the development of
Factor IXFc for the treatment of hemophilia B with significantly
improved patient convenience (in co-development with Syntonix/Biogen
Idec), stable revenues from ReFacto® (Factor VIII) and co-marketing
rights in the Nordic countries for BeneFIX® (Factor IX).

In addition, an exposition in depth was made of eight selected key
projects from the R&D portfolio:
Five specialist care projects -  Kiobrina(TM), Exinalda(TM), FIXFc
and Anti Rh(D) for two indications and three primary care projects -
5-HT2A in glaucoma, A2A in inflammation and leptin mimetic in obesity
were covered.

A few selected key highlights from the project presentations:
Kiobrina(TM), for improving growth and development of pre-term
infants, where no corresponding therapy exists today, is about to
initiate clinical phase II trials in Europe.

Regarding the primary care projects to be out-licensed, it was noted
that in the 5-HT2A project, the patient recruitment for the clinical
phase II glaucoma study is now completed and the results are expected
during the first quarter 2008.

The recruitment of patients in the A2A project clinical phase II
study in diabetic neuropathic pain is advancing according to plan,
and the results are expected during first half of 2008.

Finally, selected, exciting pre-clinical data was revealed and
presented from the leptin mimetic project, a novel approach for the
treatment of obesity.

A live broadcast from the conference will be available on Biovitrum's
website at www.biovitrum.com. The presentation material from the
conference will be available at www.biovitrum.com  under investor
relations/ presentations. A corresponding Capital Markets Day will be
held in London tomorrow, on November 8.


For more information, please contact:

Biovitrum AB (publ)

Martin Nicklasson, CEO
Phone: +46 8 697 20 00
martin.nicklasson@biovitrum.com

Göran Arvidsson, CFO
Phone: +46 8 697 23 68
goran.arvidson@biovitrum.com

Anna Karin Källén, Vice President, Corporate Communications
Phone: +46 8 697 20 85, Mobile: +46 734 33 20 85
annakarin.kallen@biovitrum.com



About Biovitrum

Biovitrum is one of the largest biopharma companies in Europe. With
operations in Sweden and in the UK Biovitrum conducts research and
develops pharmaceuticals for unmet medical needs both for conditions
that affect smaller patient populations and for common diseases.
Biovitrum has currently a broad and balanced R&D portfolio with
several projects in clinical and preclinical phases for a number of
well defined specialist indications as well as for common diseases
within obesity, diabetes, inflammation, eye and blood diseases.
Biovitrum develops and produces protein-based drugs on a contractual
basis and markets a range of specialist pharmaceuticals primarily in
the Nordic countries. Biovitrum has revenues of approximately SEK 1.2
billion and around 500 employees. Biovitrum's share is listed on the
OMX Nordic Exchange in Stockholm since September 15, 2006. For more
information see www.biovitrum.com/.